In One Stroke, Retrophin Acquires And Licenses Assets For Autism And Schizophrenia, Doubles Down On Oxytocin
This article was originally published in The Pink Sheet Daily
Executive Summary
Retrophin, the former rare disease specialist, announced an agreement to acquire Kyalin Biosciences, whose lead candidate is a synthetic oxytocin formulation for autism. On the same day, it licensed another intranasal formulation of oxytocin from Novartis, market-ready for an obstetric indication.